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Abstract
Prostate Cancer (PCa) diagnosis is currently hampered by the high false-positive rate of
PSA evaluations, which consequently may lead to overtreatment. Non-invasive methods
with increased specificity and sensitivity are needed to improve diagnosis of significant
PCa. We developed and technically validated four individual immunoassays for cathepsin
D (CTSD), intercellular adhesion molecule 1 (ICAM1), olfactomedin 4 (OLFM4), and throm-
bospondin 1 (THBS1). These glycoproteins, previously identified by mass spectrometry
using a Pten mouse model, were measured in clinical serum samples for testing the capabil-
ity of discriminating PCa positive and negative samples. The development yielded 4 individ-
ual immunoassays with inter and intra-variability (CV) <15% and linearity on dilution of the
analytes. In serum, ex vivo protein stability (<15% loss of analyte) was achieved for a dura-
tion of at least 24 hours at room temperature and 2 days at 4˚C. The measurement of 359
serum samples from PCa positive (n = 167) and negative (n = 192) patients with elevated
PSA (2–10 ng/ml) revealed a significantly improved accuracy (P <0.001) when two of the
glycoproteins (CTSD and THBS1) were combined with %fPSA and age (AUC = 0.8109;
P <0.0001; 95% CI = 0.7673–0.8545). Conclusively, the use of CTSD and THBS1 together
with commonly used parameters for PCa diagnosis such as %fPSA and age has the poten-
tial to improve the diagnosis of PCa.
Introduction
PCa is the most frequently diagnosed cancer in men and the second leading cause of male can-
cer related deaths in the US [1]. PSA is commonly used to diagnose PCa but owing to its low
specificity, can lead to false positive results and consequently to a high number of prostate
biopsies with negative diagnostic findings. Further, these unnecessary biopsies can have
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potential side effects [2,3]. Recent recommendations against widespread screening of men for
PCa using PSA [4] have resulted in fewer men being screened for PCa, and fewer early-stage
cases being detected [5].
New diagnostic tools, ideally non-invasive ones, are urgently needed to improve PCa diag-
nosis and reduce overtreatment. More accurate diagnostics from easily accessible sample types
like blood will allow physicians and patients to make more informed decisions about potential
cases of PCa and whether a prostate biopsy is required.
We have previously identified protein biomarkers for PCa diagnosis using a two-staged
genetics-guided discovery approach focusing on the PI3K/PTEN cancer pathway [6]. In the
first stage, glycoproteins were identified from sera and prostate tissue of wild-type and Pten-
null cancer mouse models. Following prioritization of the proteins, proteomic profiles were
identified in the sera of PCa patients and control individuals in a second stage validation step.
Here, our objective was to develop and validate immunoassays for the individual protein
biomarkers. The transition from mass spectrometry to immunoassay technology represents an
important step to enable high-throughput clinical validation in large sample cohorts. Further-
more, it facilitates clinical application of the test in routine diagnostic laboratories. The micro-
particle-based Luminex platform was chosen due to the improved kinetics resulting from a
higher surface area of microparticles when compared to microtiter plates or tubes [7]. In addi-
tion, magnetic microparticle-based assays are more amenable to automation than tube- or
microtiter plate-based assays [8] and thus widely distributed in random-access immunoassay
systems. Finally, the multiplexing capabilities of the Luminex system facilitated the antibody
selection process [9] for immunoassay development. It is important to note that the Luminex
assays developed were used in singleplex format for the measurement of clinical samples.
In this report, we describe the development and technical validation according to the guide-
lines from the Center for Drug Evaluation and Research (CDER) [10] of four individual
immunoassays for cathepsin D (CTSD), intercellular adhesion molecule 1 (ICAM1), olfacto-
medin 4 (OLFM4), and thrombospondin 1 (THBS1). These immunoassays were then clinically
tested in 359 serum samples of patients diagnosed with (n = 167) and without (n = 192) PCa.
All men had an elevated PSA in the range of 2–10 ng/ml. This range of PSA values is often
referred to as the “diagnostic grey zone”, because many men have benign conditions, resulting
in higher PSA values, and therefore, large number of false positive cases. Today if PSA is at
such an intermediate level, urologists might use percent free PSA (%fPSA) as an additional aid
to decide if a biopsy is necessary [11]. Our objective was to test if the additional measurement
of four glycoproteins to PSA can improve PCa diagnosis in men with elevated PSA levels.
Materials and methods
Reagents and equipment
THBS1 calibrator and antibodies were purchased from R&D Systems. Calibrator was recombi-
nant human THBS1 (3074-TH-050), the capture antibody was a mouse anti-human monoclo-
nal (MAB3074) and the detection antibody was an affinity-purified, biotinylated goat anti-
human polyclonal antibody (BAF3074). Recombinant human CTSD (residues 1–412), ICAM1
(residues 1–480) and OLFM4 (residues 1–510) were expressed and purified from cell culture
supernatants of transfected HEK293 cells using either a Ni-NTA column for CTSD and
ICAM1 or an ammonium sulfate precipitation for OLFM4 followed by a size exclusion
approach. The capture and detection antibodies were mouse monoclonals generated against
the recombinant full-length proteins of human CTSD, ICAM1 and OLFM4.
Buffers were obtained from Candor Bioscience and Roche Diagnostics. Streptavidin-phyco-
erythrin was obtained from Moss Inc. For assay development and technical validation
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purposes, blood was taken from healthy donors at Blutspende Schlieren, Switzerland and was
used exclusively for research and assay development procedures and not for clinical testing.
Blood samples were stored at 4˚C and centrifuged at 2’000g for 10 min to separate serum and
cellular fractions. The serum was aliquoted and stored at -80˚C.
The Luminex MAGPIX system was used for the assay development and measurement of
clinical serum samples and the Luminex FLEXMAP 3D system was used for technical assay
validation. xPONENT (Luminex Corp., Vers. 4.2 and 4.1) and Masterplex QT (Hitatchi, Ver.
5) were used as the acquisition and analysis software. Fluorescently coded magnetic micropar-
ticles were obtained from Luminex Corporation. Luminex Magnetic Plate Separator was used
to handle 96-well half area plates (derived from Corning) of microspheres during assay pro-
cessing steps. During incubation, the plates were placed in an Eppendorf ThermoMixer C
equipped with Eppendorf SmartBlock plates and ThermoTop. Liquid handling was performed
with calibrated, adjustable, precision pipettes.
Study population
In this case-control study, 359 serum samples from PCa positive (n = 167) and negative
(n = 192) selected from the biobanks of the Cantonal Hospital St. Gallen, Switzerland and the
Martini-Klinik, Hamburg-Eppendorf, Germany were used for testing. All samples were from
men that had a PSA between 2 and 10 ng/ml. The Cantonal Hospital St. Gallen provided 128
serum samples collected between 2004 and 2009. The study was approved by the local ethics
committee and all patients gave written informed consent. The blood samples were collected,
stored at room temperature for 15–30 min and centrifuged at 1’500g in a serum separator
tube. The serum was stored at -60˚C or lower. 56 samples were originally drawn from men
with known diagnosis of PCa and 72 samples from men without PCa (n = 72). 231 serum sam-
ples of PCa positive (n = 111) and negative men (n = 120) were selected from the Martini-Kli-
nik, Prostate Cancer Center (University Medical Center Hamburg-Eppendorf). All samples
were taken between 2011–2012 following written patient consent. The samples were allowed
to stand at room temperature for 30 min. Blood was centrifuged at 2’000g for 10 min to sepa-
rate serum and cellular fractions. The serum was stored at -80˚C.
Immunoassay development
Bead-based sandwich immunoassays were established on the Luminex system as follows: Cap-
ture antibodies were covalently conjugated to carboxylated Luminex microparticles and the
detection antibodies were labeled with biotin according to standard procedures. 96-well half
area microtiter plates (Corning Inc.) were blocked for a minimum of 15 min with 1x Blocking
Reagent for ELISA (Roche Diagnostics). The capture antibody-coated microparticle/biotiny-
lated detection antibody mix was added to the protein (sample or standard) diluted in main
assay buffer, Low Cross Buffer (LCB; Candor Bioscience) within the 96-well plate. Following a
60 min incubation at 37˚C and shaking at 650 rpm in an Eppendorf ThermoMixer C, the
plates were washed with PBS/0.05% Tween20 using a magnetic plate separator (Luminex Cor-
poration). Streptavidin-phycoerythrin conjugate (Moss Inc.) was added for 30 min, incubated
with 650 rpm at 21˚C in an Eppendorf ThermoMixer C. After washing, the bead conjugates
were resuspended in Blocking Reagent for ELISA for analysis. Read-out was performed with
either a Luminex FlexMap3D or Luminex MAGPIX instrument operated with xPONENT 4.1
or 4.2 software.
Serum total PSA (tPSA) and complexed PSA (cPSA) were analyzed using the ADVIA Cen-
taur immunoassay system (Siemens Healthcare). Percent free PSA (%fPSA) was calculated
Blood-based diagnosis of prostate cancer
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using the measured values of tPSA and cPSA with the following formula %fPSA = (tPSA-
cPSA)/tPSA100.
Immunoassay validation
Technical validation was performed following the guidelines from the Center for Drug Evalua-
tion and Research (CDER) [10]. The validation process of the bead-based immunoassays for
CTSD, ICAM1, OLFM4 and THBS1 included the assessment of sensitivity, linear range, preci-
sion, reproducibility, freeze/thaw stability, and stability at 4˚C and room temperature.
For evaluation of the assay validation parameter, at least 20 independent assay runs were
performed by four operators with no more than two assays per day and operator. The seven
standard calibrator concentrations were measured in triplicates. The LoD was determined
by measurement of 24 replicates of the zero calibrator in one assay [12]. For calculation of
LoD the mean raw data of the zero calibrator (n = 24) and the two next calibrator points
were calculated. A linear approximation between the blank and the two calibrator points was
used (line fit) for determination of the concentration of the average zero calibrator + 3 SD
value.
The LLoQ was defined as the lowest concentration of diluted calibrator protein at which
the assay still fulfilled the acceptance criteria of intra-assay precision (CV) of<25% and accu-
racy within 25% of the nominal concentration of the calibrator concentration used for prepar-
ing the individual dilutions. The ULoQ was defined as the calibrator point that showed a
precision (CV) of<20% and accuracy within 20% of the nominal concentration. Inter-assay
precision was established to test reproducibility of the assay by comparing triplicate measure-
ments of eleven samples per run on 22 independent runs on more than six different days,
done by four operators. Intra-assay precision was determined to establish reproducibility of
the assays by 18-fold measurement of 5 serum samples covering the assay range in 5 parallel
measurements.
Dilutional linearity of the individual assays was assessed by measuring 5 samples in differ-
ent serial dilutions. For evaluating short-term stability of the analyte, five individual human
serum samples were stored for up to 48 hours at 4˚C and up to 24 hours at room temperature
prior to applying the samples to the assay. The effect of these additional storage conditions was
evaluated and compared to a fresh aliquot of the same sample thawed prior to running the
assay. Freeze-thaw (F/T) stability of the analyte was determined using five individual human
serum samples. Aliquots of these samples were thawed on ice and refrozen (-80˚C) up to three
times. The recalculated values were compared to the concentration of an untreated sample
aliquot.
Statistical analysis
Statistical analysis was performed with SAS1 version 9.3 and GraphPad PRISM version 6.0.
We performed comparisons with the Mann-Whitney test not assuming normal distribution of
the data. P values<0.05 were considered significant. For the variable selection, both forward
selection (stepwise selection with entry testing based on the significance of the score statistic,
and removal testing based on the probability of a likelihood-ratio statistic based on conditional
parameter estimates) as well as backward elimination (removal testing is based on the proba-
bility of the likelihood-ratio statistic based on conditional parameter estimates) was performed
using SPSS Statistics software (version 23). Decision curve analysis was performed as described
by Vickers and Elkin [13] using RStudio1 [version 0.99.46]) an integrated development envi-
ronment for R [version 3.2.2] [14].
Blood-based diagnosis of prostate cancer
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Results
Development of four immunoassays
For all biomarkers, except for THBS1, recombinant mammalian derived protein standards
and highly specific monoclonal antibody pairs we developed. Commercially available reagents
for THBS1 were purchased from R&D Systems. The antibody selection process was performed
using the bead-based Luminex system taking advantage of the capability for multiplexing and
simultaneous testing of multiple antibody sandwich pairs. Buffer compositions and antibody
concentrations were optimized accordingly to yield the most optimal conditions for the indi-
vidual immunoassays.
For the highest calibrator concentration, full-length recombinant proteins were added to
the main assay buffer (LCB) and serially (S1-S7) diluted. The standard range for CTSD was 75
to 0.1 ng/ml using 3-fold dilution steps in LCB/0.5% Tween20. The highest final concentration
of ICAM1 was 15 ng/ml followed by 6 serial dilutions in LCB/250 mM NaCl with a dilution
factor of 2.5. Final starting concentrations for OLFM4 was 400 ng/ml followed by 1:3 dilution
steps in LCB and for THBS1, starting concentration was 92 ng/ml diluted 1:3 in LCB/0.5%
Tween20. Typical examples of calibration curves are shown in Fig 1. Interquartile ranges of the
individual markers measured in serum samples collected from healthy donors were as follows:
CTSD: 84–173 ng/ml (n = 63), ICAM1: 114–145 ng/ml (n = 43), OLFM4: 8–71 ng/ml (n = 24),
and THBS1: 24’000–34’000 ng/ml (n = 40), respectively.
Fig 1. Assay calibration curves. Representative calibration curves for the CTSD, ICAM1, OLFM4, and THBS1 assays.
https://doi.org/10.1371/journal.pone.0181557.g001
Blood-based diagnosis of prostate cancer
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Technical validation results
The LoD calculated by adding 3 SDs to the mean of 24 blanks was defined as 1.1 ng/ml for
CTSD, 1.7 ng/ml for ICAM1, 2.1 ng/ml for OLFM4, and 102 ng/ml for THBS1. The LLoQ
with an acceptance criterion of a CV<25% and a recovery of the nominal concentration
between 75–125% was calculated to be 5.2 ng/ml for CTSD, 12.0 ng/ml for ICAM1, 14.8 ng/ml
for OLFM4, and 852 ng/ml for THBS1. The ULoQ (acceptance criterion of a CV<20% and a
recovery of the nominal concentration between 80–120%) was defined as 1’125 ng/ml for
CTSD, 600 ng/ml for ICAM1, 3’200 ng/ml for OLFM4, and 368’000 ng/ml for THBS1.
The imprecision of the individual assays was determined by measuring multiple samples in
triplicates on more than five different days, performed by two operators. Intra-assay precision
(CV) for all four assays in all measured samples was<15%. The same was true for inter-assay
precision, except for one out of eleven samples (19.7%) measured by OLFM4. Intra-day preci-
sion and operator to operator variability was<15% for all assays, except for OLFM4. Table 1
describes the measuring range and precision of the four immunoassays.
Human serum samples were serially diluted and the measured concentration was recalcu-
lated considering the dilution factors. Five individual samples per analyte were measured in
triplicate to consider possible matrix differences that can exist between samples and further, to
check the recovery in samples with different initial analyte concentrations (S1 Fig). For all ana-
lytes, the test results were directly proportional to the concentration of analyte in the sample
when diluted with sample diluent. OLFM4 concentration measured in a dilution of 1:8 was
considered as the 100% reference value. For CTSD a final dilution of 1:15, for ICAM1 a dilu-
tion of 1:100 and for THBS1 a dilution of 1:4’000 was considered as the 100% reference value,
respectively.
Analyte stability was tested at room temperature in 5 different serum samples. All 4 analytes
were stable for at least 24 hours at room temperature. Mean values (as a percentage of the ini-
tial value for the samples) were 94% (range, 86–97%) for CTSD, 96% (92–101%) for ICAM1,
95% (85–98%) for OLFM4, and 94% (86–97%) for THBS1 (Fig 2) after 24 hours. For the same
samples, stability at 4˚C was tested for up to 48 hours. After 48 hours of storage, the mean mea-
sured CTSD value was 100% (96–106%) of its original value, 99% (85–106%) for ICAM1, 98%
(89–104%) for OLFM4, and 98% (90–104%) for THBS1 (Fig 2). In 5 individual human serum
samples subjected to 3 cycles of freezing and thawing, no change in the analyte concentration
was detected. The mean measured CTSD value after the third thawing was 97% (range, 95–
99%) of the original value for CTSD, 99% (90–105%) for ICAM1, 103% (94–111%) for
OLFM4, and 104% (94–117%) for THBS1 (Fig 2).
Table 1. Measuring range and precision.
Analyte LoD, ng/mL LLoQ, ng/mL ULoQ, ng/mL Inter-run CV Intra-run CV
CTSD 1.1 5.2 1’125 6.2% (3.9–9.8%) 4.2% (2.8–6.1%)
ICAM1 1.7 12.0 600 4.2% (2.3–5.5%) 6.7% (5.6–8.3%)
OLFM4 2.1 14.8 3’200 13.0% (10.6–19.7%) 7.7% (3.4–14.6%)
THBS1 102 852 368’000 4.2% (3.3–4.8%) 10.5% (9.4–12.5%)
LoD was calculated by adding 3 SD to the mean of 24 blanks. Acceptance criterion for LLoQ and ULoQ was a CV of <25% and <20%. Inter CV was
calculated by comparing triplicate measurements of 11 serum samples on 20 different runs over 5 days. Intra CV was defined by measuring 5 serum
samples in 18 replicates.
https://doi.org/10.1371/journal.pone.0181557.t001
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Clinical testing
359 men with PSA between 2 and 10 ng/ml undergoing prostate biopsy were included in this
study. 231 samples thereof were collected at the Martini-Klinik in Hamburg, Germany and
128 originated from the Cantonal Hospital St. Gallen, Switzerland. 192 men were negative for
PCa based on prostate biopsy and 167 were diagnosed with PCa (Table 2). The objective of the
study was to test if a model of one or several glycoproteins together with parameters com-
monly used for PCa diagnosis such as PSA, %fPSA or age could potentially improve the dis-
crimination of PCa positive and negative patients.
Fig 2. Stability experiments. Stability of CTSD, ICAM1, OLFM4, and THBS1 in serum stored at room temperature (RT), 4˚C or 1 up to 3
freeze and thaw (F/T) cycles, respectively. Shown are the mean (SD; error bars) measured protein concentrations (as a percentage of the
original values) in 5 different samples.
https://doi.org/10.1371/journal.pone.0181557.g002
Table 2. Patient characteristics overview.
Overall PCa negative PCa positive p-value
Number 359 192 167
Age (yrs) 66 (61–71) 68 (61–73) 64 (59–69) <0.001 †
Total PSA (ng/ml) 4.7 (3.4–6.5) 4.7 (3.2–6.3) 5.0 (3.6–6.7) 0.154 †
Free/total PSA ratio 0.14 (0.07–0.21) 0.18 (0.11–0.27) 0.10 (0.04–0.17) <0.001 †
CTSD (ng/ml) 222 (182–266) 218 (179–261) 229 (185–279) 0.125 †
ICAM1 (ng/ml) 122 (102–145) 124 (105–147) 119 (100–141) 0.074 †
OLFM4 (ng/ml) 57 (23–123) 62 (28–112) 55 (20–55) 0.296 †
THBS1 (ng/ml) 23’000 (18’000–31’000) 26’000 (20’000–36’000) 21’000 (16’000–27’000) <0.001 †
PSA = prostate specific antigen; CTSD = cathepsin D; ICAM1 = intercellular adhesion molecule 1; OLFM4 = olfactomedin 4; THBS1 = thrombospondin 1.
Data are presented as median (interquartile range).
† Mann-Whitney test.
https://doi.org/10.1371/journal.pone.0181557.t002
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First, univariate analysis of the individual protein analytes was performed (Fig 3) as well as
ROC analysis (Table 3, S2 Fig). Based on these analyses, %fPSA and THBS1 showed the best
discrimination power between PCa negative and positive men. In a next step, the individual
protein analytes as well as age were combined using logistic regression analysis. Both stepwise
forward selection as well as stepwise backward elimination yielded the same model including
CTSD, THBS1, %fPSA and age, respectively. This model discriminated between men with neg-
ative prostate biopsies and PCa bearing patients with an AUC = 0.8109 (P<0.0001; 95%
CI = 0.7673–0.8545). The combination of CTSD and THBS1 resulted in an AUC = 0.6799
(P<0.0001; 95% CI = 0.6251–0.7346), while %fPSA alone had an AUC = 0.7215 (P<0.0001;
95% CI = 0.6693–0.7736) and age an AUC = 0.6205 (P<0.0001; 95% CI = 0.5630–0.6779) as
shown in Fig 4. The combination including all four parameters was significantly better than %
fPSA and age alone (p<0.001 for both contrasts). At 90% sensitivity for PCa and NPV95%
for high-grade cancer (Gleason score7), the specificity of %fPSA, age, CTSD and THBS1
was 54%. At a more stringent sensitivity cut-off of 95% sensitivity for PCa, the specificity was
Fig 3. Univariate analysis of individual parameters. Box plots show the concentration of PSA, %fPSA, CTSD, ICAM1, OLFM4, and
THBS1 in PCa positive and negative samples.
https://doi.org/10.1371/journal.pone.0181557.g003
Table 3. Receiver operating characteristics (ROC) of the individual analytes.
Analyte AUC 95% CI p-value
PSA 0.5436 0.4839–0.6034 0.154
%fPSA 0.7215 0.6693–0.7736 <0.001
CTSD 0.5485 0.4898–0.6071 0.105
ICAM1 0.5542 0.4961–0.6123 0.070
OLFM4 0.5297 0.4709–0.5885 0.321
THBS1 0.6127 0.5507–0.6748 <0.001
PSA = prostate specific antigen; %fPSA = free to total PSA ratio; CTSD = cathepsin D; ICAM1 = intercellular
adhesion molecule 1; OLFM4 = olfactomedin 4; THBS1 = thrombospondin 1
https://doi.org/10.1371/journal.pone.0181557.t003
Blood-based diagnosis of prostate cancer
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39%. In addition, decision curve analysis was performed (S3 Fig). Determining which men
should be biopsied using the proposed method is superior to perform a biopsy in all men with
elevated PSA or using %fPSA or age, respectively, once the threshold probability reaches about
10% or 30%, respectively, and is superior to the strategy of not performing a biopsy up to a
threshold probability of about 80%.
Discussion
The discovery of new biomarkers is challenging, but even more difficult is the development of
a diagnostic method to substantiate clinical utility and ultimately to introduce it into clinical
practice [15]. Here we have translated early research findings that identified protein biomark-
ers for PCa diagnosis following a targeted proteomic strategy [16] using both mouse models
and patients cohorts, into an immunoassay-based diagnostic tool that can be applied into a
clinical test setting.
The use of a mouse model combined with state of the art mass spectrometric analysis iden-
tified promising biomarker candidates for the diagnosis of PCa [6] after initial clinical testing.
In order to overcome the analytical challenge of mass spectrometry in terms of throughput
and cost, we have developed four robust and reproducible singleplex immunoassays for the
individual protein biomarkers.
Fig 4. Receiver operating characteristics (ROC) analysis of different models. ROC curves depicting the
accuracy in predicting PCa in 359 men who had PSA levels of 2–10 ng/ml (192 PCa negative and 167 PCa
positive cases). ROC curves highlight benefits of the CTSD and THBS1 alone (blue line), %fPSA (black line),
age (brown line) and the combination of %fPSA, age, CTSD and THBS1 (red line).
https://doi.org/10.1371/journal.pone.0181557.g004
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The Luminex technology used here provided a versatile platform to develop new immuno-
assays. The multiplexing technology facilitated the identification of antibody sandwich pairs
by coupling several candidate capture antibodies to different microsphere sets. When mixed
together, these sets allowed for the simultaneous testing of separate detection antibodies saving
reagents, sample and time [9]. In addition, the reagents including antibodies and protein
standards selected for the microparticle-based assays are transferable to both microtiter plate-
based assays as well as potentially to random-access systems used in routine diagnostics. Given
the large difference in protein concentration and thus the resulting difference in assay dilution
as well as the use of different assay buffers prohibited direct multiplexing and thus the mea-
surement was carried out in singleplex format. Nevertheless, the assays can potentially be fur-
ther developed to be used in a multiplexed fashion even though immunoassay platforms with
multiplexing-capabilities are rarely used today in clinical routine diagnostic.
We determined the performance of the individual assays according to standard guidelines
[10]. While there might still be room for improvement for some of the assay specifications, the
assays are stable and reproducible and can thus be used for evaluation in larger clinical studies.
The clinical results reported here further evaluated the role of the four glycoproteins CTSD,
ICAM1, OLFM4 and THBS1, formerly identified using mass spectrometry-based measure-
ments in early PCa diagnosis. The function of all four glycoproteins is covered by the major
hallmarks of cancer development as defined by Hanahan and Weinberg [17] including apopto-
sis, angiogenesis and metastasis. OLFM4 was shown to be an important regulator of apoptosis
in murine prostate tumor cells [18]. THBS1 was reported to be a regulator of angiogenesis in
malignant and nonmalignant prostate tissue [19]. Furthermore, it was demonstrated that both
CTSD and ICAM1 were promoting malignancy in the prostatic epithelium [20,21].
In this study setting, only THBS1 and %fPSA were significantly different in abundance in
univariate analysis between the PCa positive and negative group, but CTSD proofed to have
an additional statistically significant (P = 0.001) benefit when combined with THBS1, while
ICAM1 and OLFM4 did not.
Both THBS1 and CTSD have been shown to be involved in PCa development [22,23]. The
anti-angiogenic THBS1 suppresses the neovascularization from the existing vascular system
and thus inhibits tumor growth [24,25] by directly regulating VEGF [26]. THBS1 expression
was reported to inversely correlate with malignant progression [24,27]. Specifically, THBS1
immunostaining was shown to be highly positive in the benign stromal tissue and only weakly
positive in the peritumoral tissue of PCa [25]. In addition, the same was shown in preclinical
models as well as in patients with various types of cancer, including melanoma, breast, lung
and bladder cancer [28–31]. Cathepsins in general are known to be highly expressed in various
human cancers, associated with tumor metastasis [32]. CTSD was shown to be overexpressed
and secreted by several types of tumor cells including lung, breast and PCa [23]. Immunohisto-
chemical examination of CTSD was shown to reveal low levels of expression in normal pros-
tate tissue and prominent stromal expression in malignant areas of the prostate [20]. Several
studies have already suggested that CTSD acts as an essential mediator to promote malignancy
of benign prostatic epithelium and therefore might be useful in differentiating benign from
malign prostatic disease [33–35].
The combination of CTSD, THBS1, %fPSA and age showed clear improvement in terms of
higher AUC and specificity when compared to %fPSA alone. More specifically, the results of
our study showed 55% specificity at a high NPV (95%) for high-grade cancer (Gleason score
7) indicating that in clinical practice more than half of the negative biopsies could have been
prevented at a low likelihood of delaying the diagnosis of significant PCa. In addition, we
employed decision-analytic methods to evaluate the potential impact of the method presented
here in clinical practice. Decision analysis proposes it might be an effective method in deciding
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whether to biopsy or not. This confirms the added value of two of four cancer-specific protein
biomarkers (CTSD and THBS1) and their complementarity to the standard %fPSA test.
In 2012, a US national task force found that the risks of routine PSA screening outweigh the
benefits. Recently, two new studies confirmed that the recommendation against PSA screening
was associated with a change in biopsy and cancer detection rates. The studies reported that
fewer early-stage PCa in general and fewer high-grade cancers in particular are being detected
as fewer men are being screened [36,37]. Thus, there is an urgent need for improving the high
false-positive rate of PSA for early PCa detection. Similar methods and markers for the diagno-
sis of PCa have been described for non-invasive testing in blood [38] and urine [39]. Two
similar tests composed of kallikrein panels are available for blood-based testing. The Prostate
Health Index test analyzes total, free and a precursor of PSA (p2PSA) [40] while the 4KScore
includes total, free, intact PSA and human kallikrein 2 (hK2) [41]. The PCA3 test is a gene-
based test in urine [42]. Similar tests exist for the detection of urine-based TMPRSS2:ERG
fusion in combination with PCA3 [43] or a molecular signature of PCA3 and ERG exosomal
RNA from urine [44]. Recently, a model including a combination of plasma protein biomark-
ers, genetic polymorphisms and clinical variables was evaluated in a large prospective popula-
tion-based diagnostic study in Stockholm [45].
Larger, prospective multicenter studies are already ongoing to further validate the findings
presented here. Ultimately, the method presented is intended to be used as a reflex-test if the
PSA is increased, complementary to the existing %fPSA as an aid in distinguishing PCa from
benign prostatic conditions. Prostate biopsy will still be required for diagnosis of PCa.
In conclusion, we provide evidence that the newly developed method presented here
including the measurement of CTSD and THBS1 in combination with %fPSA and age shows
improved performance in diagnosing PCa.
Supporting information
S1 Fig. Dilutional linearity experiments. The y-axis shows the analyte concentration as deter-
mined by the individual immunoassay tests using 5 serum samples for the individual immuno-
assay of CTSD, ICAM1, OLFM4, and THBS1.
(EPS)
S2 Fig. Receiver operating characteristics (ROC) analysis of individual parameters. ROC
curves depicting the accuracy in predicting positive biopsy in 359 men who underwent pros-
tate biopsy and who had PSA levels of 2–10 ng/ml (192 controls and 167 PCa cases). (A) ROC
curve of PSA (black line), %fPSA (purple line), CTSD (orange line), ICAM1 (brown line),
OLFM4 (blue line), and THBS1 (red line) are shown.
(EPS)
S3 Fig. Decision curve analysis showing the effect of the four models on the detection of
PCa. Clinical net benefit for the models is plotted against the risk threshold at which a patient
or clinician would opt for biopsy. As a comparison, the gray line represents the strategy of per-
forming a biopsy in all men, and the black line represents the strategy of no men undergoing
biopsy.
(TIF)
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